MoonLake Immunotherapeutics Class A Ordinary Shares
MLTXMoonLake Immunotherapeutics is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating treatments that harness the body's immune system to target and combat cancer, with an emphasis on complement pathway modulation. Its pipeline includes a variety of investigational drugs aimed at improving outcomes for patients with difficult-to-treat cancers.
Company News
MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 39,120 shares worth approximately $862,000 on June 22 through a pre-planned 10b5-1 trading plan. The sale represented 3.4% of his direct holdings, leaving him with over 1.1 million shares. While the transaction shouldn't concern investors due to its pre-planned nature, the clinical-stage bi...
MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech company, announced the pricing of an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and 1 million pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The company plans to use the net proceeds to fund researc...
MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 shares worth approximately $2.8 million on April 10-13, 2026, reducing his direct holdings by 4.9%. While the sale is not necessarily alarming given his substantial remaining stake of nearly 3 million shares, the company remains a high-risk investment. MoonLake's stock has fallen ...
BVF Partners L.P., a biotech-focused hedge fund, sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million on April 2, 2026, reducing its direct stake by 78.3%. The sale appears to be portfolio rebalancing rather than a full exit, as BVF retains 15.9 million shares. MoonLake, a clinical-stage immunotherapy company deve...
MoonLake Immunotherapeutics announced Week 40 results from its Phase 3 VELA clinical trials of sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The drug demonstrated continued clinical improvement with 62% of patients achieving HiSCR75 response and up to 32% achieving HiSCR100. Patients also showed substantial improvements ...
